Drug Trial Radar · NCT07344376
An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)
Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
May 23, 2018
Primary completion
Dec 30, 2022
Study completion Dec 30, 2022
Sponsor
- Lead sponsor
- GC Biopharma CorpIndustry
- Sponsor type
- Industry
- Collaborators
- Samsung Medical Center
- First posted
- Jan 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the long-term safety and efficacy of Hunterase for approximately 1 year in subjects who completed the end of study (EOS) visit (Visit 54) tests in the Phase 3 Hunterase study and patients who received Hunterase for more than 6 months
Conditions
- MPS II
- Hunter Syndrome (MPS II)
- Hunter Syndrome
- Hunterase
- GC1111
Interventions
HunteraseDrug
0.5mg/kg weekly IV administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Laboratory tests (CBC, Chemistry, Urinanalysis)Time frame: Every visit until 12months
- Physical examinationTime frame: Every visit until 12months
- Adverse EventTime frame: Every visit until 12months
- ElectrocardiographyTime frame: Every 6 months until 12months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.